Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674386 | 0.93 | PTPN1 (0.61) | PTPN1ACEPTPN22CTSSCTSK | |
| SCHEMBL7117053 | 0.89 | PTPN1 (0.52) | PTPN1ITGB3ITGA2BITGA4ITGB7 | |
| SCHEMBL4650261 | 0.88 | PTPN1 (0.51) | PTPN1ACEPTPN22CTSSCTSK | |
| SCHEMBL7680157 | 0.85 | PTPN1 (0.56) | PTPN1ACEPTPN22CTSSCTSK | |
| SCHEMBL4650405 | 0.84 | PTPN1 (0.53) | PTPN1PTPN22CTSSCTSKCTSB | |
| SCHEMBL7672421 | 0.84 | PTPN1 (0.58) | PTPN1PTPN22CTSSCTSKCTSB | |
| SCHEMBL2328680 | 0.82 | PTPN1 (0.56) | PTPN1ITGB3ITGA2BACEITGA4 | |
| SCHEMBL2328686 | 0.82 | PTPN1 (0.56) | PTPN1ITGB3ITGA2BACEITGA4 | |
| SCHEMBL10883770 | 0.82 | ITGB3 (0.67) | PTPN1ITGB3ITGA2BACEITGA4 | |
| SCHEMBL3811846 | 0.80 | ACE (0.57) | PTPN1ITGB3ITGA2BACEITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315760-B1 | PIPERAZINE COMPOUNDS WITH HERBICIDAL EFFECT | BASF SE (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-1791825-B1 | BENZOYL-SUBSTITUTED SERINE AMIDES | BASF SE (DE) | 2008-09-17 | — | — | EP | disclosed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1773787-A1 | METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO)URACILS AND DITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010474-A1 | METHOD FOR THE PRODUCTION OF 3-PHENYL(THIO)URACILS AND DITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2006-02-02 | — | — | WO | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | PTPN1 5/4885ITGB3 3242/4885ITGA2B 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.